Pages that link to "Q38256840"
Jump to navigation
Jump to search
The following pages link to Bevacizumab for choroidal neovascularization secondary to age-related macular degeneration and pathological myopia (Q38256840):
Displaying 5 items.
- A Comprehensive Review of Clinical Trials on EGFR Inhibitors Such as Cetuximab and Panitumumab as Monotherapy and in Combination for Treatment of Metastatic Colorectal Cancer (Q26775711) (← links)
- Ranibizumab and aflibercept for the treatment of wet age-related macular degeneration (Q38528148) (← links)
- EFFICACY AND SAFETY OF RANIBIZUMAB FOR THE TREATMENT OF CHOROIDAL NEOVASCULARIZATION DUE TO UNCOMMON CAUSE: Twelve-Month Results of the MINERVA Study (Q38680981) (← links)
- Vascular endothelial growth factor inhibitor use and treatment approach for choroidal neovascularization secondary to pathologic myopia (Q38778027) (← links)
- Intravitreal administration of bevacizumab: pros and cons (Q39865676) (← links)